Genomic Health (NASDAQ:GHDX) will be posting its quarterly earnings results after the market closes on Monday, February 12th. Analysts expect Genomic Health to post earnings of $0.08 per share for the quarter.

Genomic Health (NASDAQ:GHDX) last announced its quarterly earnings data on Wednesday, November 8th. The medical research company reported $0.03 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.01) by $0.04. The firm had revenue of $83.82 million for the quarter, compared to the consensus estimate of $87.06 million. Genomic Health had a negative net margin of 1.30% and a negative return on equity of 1.79%. On average, analysts expect Genomic Health to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Shares of Genomic Health (NASDAQ GHDX) opened at $33.52 on Friday. The stock has a market cap of $1,170.00, a PE ratio of -257.85 and a beta of 0.59. Genomic Health has a one year low of $26.54 and a one year high of $37.50.

A number of equities research analysts have issued reports on GHDX shares. Jefferies Group reiterated a “hold” rating and set a $34.00 price objective on shares of Genomic Health in a research note on Friday, October 20th. ValuEngine downgraded shares of Genomic Health from a “hold” rating to a “sell” rating in a research note on Thursday, November 9th. Canaccord Genuity reiterated a “buy” rating and set a $39.00 price objective on shares of Genomic Health in a research note on Wednesday, November 15th. JPMorgan Chase & Co. downgraded shares of Genomic Health from a “neutral” rating to an “underweight” rating and set a $25.00 price objective on the stock. in a research note on Wednesday, December 13th. Finally, BidaskClub upgraded shares of Genomic Health from a “sell” rating to a “hold” rating in a research note on Tuesday, December 19th. Three research analysts have rated the stock with a sell rating, seven have given a hold rating and one has assigned a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus target price of $32.33.

In other news, insider Phillip G. Febbo sold 5,334 shares of the stock in a transaction dated Tuesday, December 19th. The shares were sold at an average price of $36.99, for a total value of $197,304.66. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Kimberly J. Popovits sold 10,000 shares of the stock in a transaction dated Tuesday, January 16th. The stock was sold at an average price of $34.99, for a total transaction of $349,900.00. The disclosure for this sale can be found here. Insiders sold 69,338 shares of company stock valued at $2,305,951 in the last three months. Company insiders own 46.20% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Genomic Health (GHDX) to Release Earnings on Monday” was originally published by TheOlympiaReport and is the property of of TheOlympiaReport. If you are reading this news story on another publication, it was illegally copied and republished in violation of US & international copyright legislation. The correct version of this news story can be accessed at https://theolympiareport.com/2018/02/11/genomic-health-ghdx-to-release-earnings-on-monday.html.

About Genomic Health

Genomic Health, Inc is a healthcare company that provides genomic-based diagnostic tests to personalize cancer treatment. The Company develops and commercializes genomic-based clinical laboratory services. The Company’s Oncotype IQ Genomic Intelligence Platform is consisted of its flagship line of Oncotype DX gene expression tests, as well as its Oncotype SEQ Liquid Select test.

Earnings History for Genomic Health (NASDAQ:GHDX)

Receive News & Ratings for Genomic Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health and related companies with MarketBeat.com's FREE daily email newsletter.